Induced stem cells

Insights on the Primary Cells Global Market to 2028 - by Type, End-use, Source and Regions - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021
Health, Other Health, Stem cells, Regenerative biomedicine, Emerging technologies, Academic disciplines, Cell biology, Articles, Biological engineering, Induced stem cells

The "Primary Cells Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use; By Source; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Primary Cells Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use; By Source; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global primary cells market size is expected to reach USD 1.79 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The different types of primary cells include hematopoietic, hepatocytes, renal cells, gastrointestinal cells, skin cells, lung cells, and others.

Global Induced Pluripotent Stem Cells Markets 2021-2026: Molecular and Cellular Engineering, Cellular Reprogramming, Cell Culture, Cell Differentiation, and Cell Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, Stem cells, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Stem cell genomics

The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • For this report, iPSC products do not cover stem cell research and clinical products, which are broadly applicable to any stem cell type.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSCs market.

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Cell therapy

Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.

Key Points: 
  • Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.
  • iPSCs are cells that can be differentiated into various cell types to address a wide range of therapeutic indications.
  • "We formed RheinCell based on our deep scientific and regulatory expertise in the promising field of cell-based therapies," commented Juergen Weisser, Chief Executive Officer, RheinCell Therapeutics.
  • RheinCell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.

SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

Retrieved on: 
Wednesday, June 23, 2021
Research, Infectious diseases, Genetics, Clinical trials, Stem cells, Biotechnology, Health, Science, Oncology, Branches of biology, Biology, Life sciences, Biotechnology, Induced stem cells, Stem cells, Cloning, Cell biology, Induced pluripotent stem cell

The regenerative medicine research was presented at the 2021 International Society for Stem Cell Research virtual annual meeting.

Key Points: 
  • The regenerative medicine research was presented at the 2021 International Society for Stem Cell Research virtual annual meeting.
  • We are excited by these preclinical proof-of-concept data demonstrating that we can rapidly generate neurons with mature markers using optimized, transient mRNA transcription factor expression.
  • Cell Squeeze technology can generate reprogrammed cells by controlling the magnitude and timing of single or multiple cell programming factors.
  • Together these data show the potential of the Cell Squeeze technology to rapidly reprogram cells for regenerative medicine applications.

NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy

Retrieved on: 
Tuesday, June 22, 2021
Data management, Health, Technology, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Induced stem cells, Developmental biology, Cancer screening, NanoString Technologies, Stem cell, Assay, ARMI-BioFabUSA, NanoString Technologies, Inc., ARMI-BIOFABUSA, NANOSTRING TECHNOLOGIES, INC.

The new nCounter Stem Cell Characterization panel measures the eight essential components of stem cell biology and provides a novel, standardized assay for evaluating factors that influence and determine viability, functionality, and pluripotency.

Key Points: 
  • The new nCounter Stem Cell Characterization panel measures the eight essential components of stem cell biology and provides a novel, standardized assay for evaluating factors that influence and determine viability, functionality, and pluripotency.
  • To learn more about the nCounter Stem Cell Characterization Panel, visit NanoString at the virtual 2021 ISSCR Conference June 21-26 .
  • To learn more about the panel and how the development of the panel can expedite stem cell research, visit the Brief nCounters stem cell experience.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s

Retrieved on: 
Monday, June 21, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Other Health, Biotechnology, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Induced stem cells, Cloning, Mesenchymal stem cell, Stem-cell therapy, Cell therapy

This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.

Key Points: 
  • This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.
  • HBSCRF will become the first research organization in the U.S. to conduct simultaneous trials examining effects of administering the patients own cells (autologous) and donor cells (allogeneic) on the same disease condition.
  • We have to explore every facet of how adipose-derived mesenchymal stem cells act in this disease condition, says HBSCRF Founder Donna Chang.
  • Our primary research focus has always been on autologous stem cells, but in COVID, for example, when we ran three simultaneous studies in prevention and treatment, we encountered a situation where people needed cells but did not have their stem cells banked.

Yushangmei acquires American company Totally Green Inc. to accelerate its vision to establish an international expansion platform

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cloning, Induced stem cells, Cell biology, Developmental biology, Stem cell

Pursuant to the Sale and Purchase Agreement, Yushangmei proposes to acquire and Totally Green intends to sell the controlling stake in the target company (or its holding company).

Key Points: 
  • Pursuant to the Sale and Purchase Agreement, Yushangmei proposes to acquire and Totally Green intends to sell the controlling stake in the target company (or its holding company).
  • Yushangmei owns a range of high-tech health products such as Fuhengbao, Miaoyiyan, and Jinshubao, which mainly focus on women's personal health care and are developed by self-dependent technology.
  • The company has cooperated intensively with the R&D institutions for high-tech female reproductive health product, stem cells,biomedicine and universities in Mainland China.
  • What's more, with the use of digitalized technology, e-commerce system platform is perfectly created, while online and offline businesses are highly integrated.

MCI Onehealth Provides Update on Investment in Acorn Biolabs Inc., Provider of Patented Stem Cell Collection Technology

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Acorn, Ornaments, Quercus, Stem cell, MCI, Hair follicle

In addition to the capital investment, MCI will be providing commercial support to Acorn by including Acorns patented stem cell collection services in MCIs selection of service offerings.

Key Points: 
  • In addition to the capital investment, MCI will be providing commercial support to Acorn by including Acorns patented stem cell collection services in MCIs selection of service offerings.
  • In July 2021, select MCI clinics will begin offering Acorns services, including non-invasive hair follicle-based stem cell collection and storage, as well as live cell and genetic analytics.
  • MCI anticipates that Acorns services will become available throughout the entire MCI network by the end of the year.
  • Acorns patented technology allows for non-invasive stem cell collection and cryostorage as a monthly subscription service, in addition to providing next-generation genetics and live cell analytics.

Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

Retrieved on: 
Thursday, June 17, 2021
Life sciences, Biology, Branches of biology, Biotechnology, Cell biology, Stem cells, Caladrius Biosciences, Induced stem cells, Biopharmaceutical, Cell therapy

The Companys presentation will begin today, June 17th at 10:30 a.m. Eastern time and consist of a 20-minute corporate overview and research update, followed by a 20-minute Q&A session moderated by a Noble Capital Markets equity research representative.

Key Points: 
  • The Companys presentation will begin today, June 17th at 10:30 a.m. Eastern time and consist of a 20-minute corporate overview and research update, followed by a 20-minute Q&A session moderated by a Noble Capital Markets equity research representative.
  • The presentation can be accessed in two ways: by registering for the full World Stem Cell Summit www.worldstemcellsummit.com, or by completing the free registration for the Investor Forum only at www.channelchek.com .
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease.
  • We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body.

Global Cell Isolation (Human Cells and Animal Cells) Market Research Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Cloning, Induced stem cells, Cell biology, Laboratory techniques, Stem cell, Cell isolation, Centrifugation, Stemcell Technologies

Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell.

Key Points: 
  • Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell.
  • The Global Cell Isolation Market has been segmented into product, cell type, source, technique, application, end-user, company and region.
  • Based on technique, the market is further fragmented into centrifugation-based cell isolation, surface-marker based cell isolation and filtration-based cell isolation, amongst which, centrifugation-based cell isolation segment occupied the largest market share in 2020 as it finds extensive applications in various end-user sectors such as academic institutes, research laboratories, etc.
  • Based on application, the market is further divided into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics and others.